Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 5/20 | 0.39 |
| ▸ | CDK2 | P24941 | 5/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.35 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.35 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24605551 | 1.00 | CCNE1 (0.39) | CCNE1CDK2CCNT1FYNPARP14 | |
| SCHEMBL27197101 | 0.87 | CCNE1 (0.43) | CCNE1CDK2CCNT1FYNPARP14 | |
| SCHEMBL29776505 | 0.86 | CCNE1 (0.43) | CCNE1CDK2CCNT1FYNPARP14 | |
| SCHEMBL24605559 | 0.86 | CCNE1 (0.43) | CCNE1CDK2CCNT1FYNPARP14 | |
| SCHEMBL27197214 | 0.77 | MAPK1 (0.42) | CCNE1CDK2CCNT1FYNPARP14 | |
| SCHEMBL27196848 | 0.77 | CCNE1 (0.40) | CCNE1CDK2CCNT1FYNPARP14 | |
| SCHEMBL29776336 | 0.77 | MAPK1 (0.42) | CCNE1CDK2CCNT1FYNPARP14 | |
| SCHEMBL27196936 | 0.75 | ABL1 (0.47) | — | |
| SCHEMBL27196906 | 0.75 | CCNE1 (0.40) | CCNE1CDK2CCNT1PARP14MAPK14 | |
| SCHEMBL27197126 | 0.74 | CCNE1 (0.42) | CCNE1CDK2CCNT1FYNMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CELGENE CORPORATION (US) | 2024-04-18 | — | — | US | disclosed |
| EP-4267131-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2023-11-01 | — | — | EP | disclosed |
| CN-116685318-A | Heterocyclic compounds and their use for parasitic diseases | 细胞基因公司 | 2023-09-01 | — | — | CN | disclosed |
| WO-2022146920-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CYP11B2, CYP11B1, CYP8B1 | CCNE1 234/4885CDK2 69/4885CCNT1 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.